Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 15/20 | 0.36 |
| ▸ | RARB | P10826 | 4/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
| ▸ | CSF3R | Q99062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20313575 | 0.97 | FFAR4 (0.35) | FFAR4RARBFFAR1RARARARG | |
| SCHEMBL20407343 | 0.96 | FFAR4 (0.35) | FFAR4RARBFFAR1 | |
| SCHEMBL20313572 | 0.93 | FFAR4 (0.36) | FFAR4RARBFFAR1RARARARG | |
| SCHEMBL19856124 | 0.92 | FFAR4 (0.33) | FFAR4RARB | |
| SCHEMBL20313568 | 0.91 | RARB (0.41) | FFAR4RARBRARARARG | |
| SCHEMBL19854220 | 0.91 | RARB (0.39) | FFAR4RARBRARARARG | |
| SCHEMBL20313571 | 0.90 | FFAR4 (0.35) | FFAR4RARBFFAR1RARARARG | |
| SCHEMBL19855963 | 0.89 | FFAR4 (0.34) | FFAR4RARBFFAR1RARARARG | |
| SCHEMBL20313567 | 0.89 | RARB (0.41) | RARBRARARARG | |
| SCHEMBL19855951 | 0.87 | FFAR4 (0.34) | FFAR4RARBFFAR1RARARARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| EP-3351525-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-06-28 | — | — | US | disclosed |
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | C1S, CCND1, C5 | FFAR4 1865/4885RARB 3791/4885FFAR1 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.